L

ast fall, Allergan (AGN) transferred rights for six patents to a best-selling eye drug to a Native American tribe, focusing unprecedented attention on a type of patent challenge that vexes brand-name drug makers. Called inter partes reviews, these are heard before a U.S. Patent and Trademark Office appeals board, not a court, and are generally easier and faster to pursue than more conventional patent lawsuits.

Not surprisingly, there are more of these challenges being filed than ever before.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It’s infuriating to have the Globe list an article and then find out you have to pay a third party to read it. Soon, can I expect to see Henry walking the streets of Boston wearing a signboard hawking diet pills and car insurance?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy